Article

AI-driven design of Novel EGFR Inhibitors with Enhanced Potency and Drug-Like Properties

2025-06-30

Abstract excerpt

<title>Abstract</title> <p>The Epidermal Growth Factor Receptor (EGFR) is a clinically validated target in oncology, with aberrant EGFR signaling implicated in several cancers, including non-small cell lung cancer and glioblastoma. While existing EGFR inhibitors have shown therapeutic success, challenges such as acquired resistance, suboptimal drug-likeness, and limited affinity for mutant receptor variants persi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9abe7feb-1698-5f61-8edb-8ad496cb873d
DOI: 10.21203/rs.3.rs-6888580/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

AI-driven design of Novel EGFR Inhibitors with Enhanced Potency and Drug-Like PropertiesDOI 10.21203/rs.3.rs-6888580/v1Read

LigEGFR: Spatial graph embedding and molecular descriptors assisted bioactivity prediction of ligand molecules for epidermal growth factor receptor on a cell line-based datasetSemantic proximity Read

Machine learning-guided drug repurposing for EGFR inhibition using scaffold-split validation, docking, and molecular dynamics.Semantic proximity Read

PROtein Analytics for Kinase Therapeutic Inhibitor Variants (PROAKTIV): A Machine learning approach to predict efficacy of tyrosine kinase inhibitors against mutations in EGFR, ALK and BRAFSemantic proximity Read

Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations.Semantic proximity Read

Discovery of EGF Receptor Inhibitors That Are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design.Semantic proximity Read

Machine learning-aided discovery of T790M-mutant EGFR inhibitor CDDO-Me effectively suppresses non-small cell lung cancer growth.Semantic proximity Read

DeepAEG: A model for predicting cancer drug response based on data enhancement and edge-collaborative update strategiesSemantic proximity Read

DeepEAG: An edge-powered graph neural network using SMILES augmentation for cancer drug response predictionSemantic proximity Read

Building 2D classification models and 3D CoMSIA models on small-molecule inhibitors of both wild-type and T790M/L858R double-mutant EGFR.Semantic proximity Read

Toward structure-based drug design against the epidermal growth factor receptor (EGFR).Semantic proximity Read

Single and Multi-Objective Optimization of De Novo Drug Design for Sophisticated Biomarkers, RET AlterationsSemantic proximity Read

QSAR-based models for designing quinazoline/imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFR.Semantic proximity Read